Skip to main content

Micregen

INVESTORS
INVESTORS & PARTNERS
Ten Years Of Work. One Remaining Dependency.

We are looking for capital to manufacture clinical-grade material and take MRG1061 into trials for premature infants who currently have no approved drug treatment. We consider this true impact investing.

What Is Already Done
  • The science. Preclinical efficacy demonstrated in NEC and BPD models with The Hospital for Sick Children (SickKids), Toronto, Great Ormond Street Hospital, London and Washington University, and in further tissue models at the University of Reading. Several published papers
  • The regulatory. Accepted onto the MHRA’s Innovative Licensing and Access Pathway; Innovation Passport granted; orphan designation being pursued.
  • The manufacturing. GMP master and working cell banks manufactured with Merck. 21 in-process-control and release assays developed, including Over 4 years of stability data. Three manufacturing partners identified, costed and ready to contract.
  • The intellectual property. Worldwide rights owned outright, with no university or third-party claim.
  • The people. A clinical advisory panel drawn from the leading NEC and neonatal intensive care centres in the UK and Canada, and a trial designed with the surgeons to run it.
What Funding Starts
  • Manufacture of clinical-grade MRG1061
  • GLP safety and toxicology
  • Clinical Trial Application to the MHRA
  • First-in-human Phase 1/2a trial in NEC, in a UK neonatal intensive care
Three Conversations We Are Having
Investment

To fund clinical manufacture, the safety package and the CTA.

Licensing
We intend to license MRG1061 following initial safety and efficacy data. We are open to earlier conversations with partners who wish to be positioned before that point.
Longevity partnering
The longevity applications of the platform are held under Anageria™ and are available now to a partner able to take them forward independently of the NEC programme.
Nothing on this website constitutes an offer or solicitation to invest.
If you want to see the full picture

The complete data package, manufacturing plan, regulatory correspondence and financial detail are available under confidentiality. Enquiries are handled directly and personally.

Get in touch with us
Contact Us
Making an Impact Investment

A recent survey conducted by the Department for International Development highlighted that more than 68% of savers in the UK wanted their investments to be good for people and the planet. This sentiment is well aligned with Micregen’s ambition.

Investing for positive impact goes beyond avoiding harm and mitigating risks and is at the centre of a broader movement towards more responsible investing.

For Investors, Micregen meets the following criteria:
Early deal access to a private company targeting an emerging area of life science
Disruptive first-in-class opportunity
Ambitious strategy to address areas of high unmet need
Significant global market potential
Proprietary platform technology with potentially wide utility across diseases
Highly scalable opportunity
EIS Relief for qualifying investors
Experienced and passionate team capitalising on the founders’ lifetime work
Extensive Key Opinion Leaders (KOL) advisor network & 3rd party validation
An ethical business aiming to generate a meaningful difference to society.

If you want to see the full picture

The complete data package, manufacturing plan, regulatory correspondence and financial detail are available under confidentiality. Enquiries are handled directly and personally.

Investment Form